Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10478MR)

This product GTTS-WQ10478MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10478MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14603MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ1396MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ6283MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ15058MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ12772MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ9421MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ11379MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ3650MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1187982
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW